National and International Guidelines include TARGIT-IORT for breast cancer

TARGIT-IORT is used in over 250 centres in 35 countries, and included in most national and international guidelines: 

During the COVID-19 pandemic, new guidelines for treatment of beast cancer  and radiotherapy especially recommend using TARGIT-IORT because it would save patients the daily travel (and viral exposure) to radiotherapy departments:

Global radiation oncology's targeted preparedness for COVID-19 

“where the technology is available the use of IORT may obviate the need for any further outpatient treatment and should be considered an option ..” 


British Association of Cancer Surgery (BASO~ACS)

German University Hospitals

Italian Association of Radiotherapy and Clinical Oncology

Implementation of breast cancer continuum of care in low- and middle-income countries during the COVID-19 pandemic


Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group

The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience

China is increasing its use of TARGIT-IORT #breastcancer by equipping more centres with the TARGIT-IORT equipment 


Previously, TARGIT-IORT has been recommended by


NICE, the UK National Institute for Health and Care Excellence recommended TARGIT-IORT to be used in the NHS wherever the expertise and equipment is available.

Marmot committee on screening mammography in the UK 


German Gynaecology Oncology group (AGO) 

German S3 guidelines

St Gallen International Breast Cancer Consensus 


European Society of Breast Cancer Specialists EUSOMA  


European Society of Medical Oncology ESMO 


Australian counterpart of UK NICE - the Medical Services Advisory Committee$File/1189-FinalPSD-IORTforEarlyBreastCancer-accessible.pdf


American Cancer Society 10/n


American Society of Breast Surgeons 


Follow us

  • Facebook - White Circle
  • Twitter - White Circle